Ovarian Hyperstimulation Syndrome. Hyperstimulation of ovaries
Conditions
Interventions
Intervention 1: Intervention Group 1: Oral administration of letrozole tablets (2.5 mg daily), manufactured by Aburaihan Pharmaceutical Co., chemical formula C17H11N5, one tablet per day for 7 consecu
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
No minimum to 35 Years
Inclusion criteria
Inclusion criteria: Having 10 follicles in each ovary during ovarian stimulation cycle Use of GnRH Agonists in Ovarian Stimulation Ovarian Hyperstimulation Syndrome
Exclusion criteria
Exclusion criteria: Hyponatremic or hyperkalemic patients Thromboembolic risk
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of ovarian hyperstimulation syndrome. Timepoint: 2 to 3 weeks after the intervention. Method of measurement: Clinical symptoms such as abdominal pain and nausea, along with ultrasound findings and blood test results. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization requirement. Timepoint: (1) during the initial 7-day period following oocyte retrieval, representing the peak risk window for OHSS development; (2) immediately upon emergence of any severe symptoms, regardless of study phase; and (3) during the final evaluation at 2 weeks post-intervention to capture delayed-onset cases. Method of measurement: Medical History (Hx). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Pooneh Amani
Zahedan University of Medical Sciences
Outcome results
None listed